How does Cellectar's current valuation metrics (e.g., EV/Revenue, EV/EBITDA) compare to comparable oncology biotech companies?

Short answer:

The press release you shared does not contain any of the numbers needed to calculate Cellectar Biosciences’ (CLRB) valuation multiples (enterprise value, revenue, EBITDA, etc.). Consequently, I can’t give you a point‑for‑point comparison to other oncology‑focused biotech firms from this source alone.

Below is a step‑by‑step guide (and some market‑wide context) that will let you pull the required data, compute the multiples, and see how Cellectar stacks up against its peers.

1. What you need to calculate the key multiples

2. Quick “rule‑of‑thumb” ranges for late‑stage oncology biotech companies (2023‑2024 data)

These ranges are *illustrative*; exact numbers shift with market sentiment, interest‑rate environment, and the perceived regulatory risk of the pipeline.

3. How to actually compute Cellectar’s multiples

1. Gather the raw numbers (as of the most recent close, e.g., 13‑Aug‑2025):

   • Market Cap: Look up CLRB’s share price × shares outstanding.
     
   • Total Debt: Usually minimal for a cash‑burn biotech, but check the balance sheet for any convertible notes, term loans, or revolving credit facilities.
     
   • Cash & Cash Equivalents: From the latest 10‑Q (Q2‑2025) or the most recent quarterly filing.
     
   • Revenue (TTM): Add Q2‑2025 revenue to the prior nine months of revenue (Q3‑2023, Q4‑2023, Q1‑2024, Q2‑2024, Q3‑2024, Q4‑2024, Q1‑2025). Many early‑stage biotech firms report $0‑$5 M in annual revenue, often from licensing or collaboration milestones.
     
   • EBITDA (TTM): If not disclosed, calculate Operating Income + D&A, or simply note that it is likely a loss.
     

2. Compute EV:
   
   [
   \text{EV} = \text{Market Cap} + \text{Total Debt} - \text{Cash}
   ]

3. Calculate multiples:
   
   [
   \text{EV/Revenue} = \frac{\text{EV}}{\text{Revenue (TTM)}}
   ]
   
   [
   \text{EV/EBITDA} = \frac{\text{EV}}{\text{EBITDA (TTM)}}
   ]

4. Benchmark:

   • Pull the same figures for each peer.
     
   • Compute median, 25th, and 75th percentiles for the peer set.
     
   • Plot Cellectar’s multiples against those percentiles to see whether it’s “cheap,” “fair,” or “expensive” relative to peers.

4. Why EV/EBITDA often isn’t useful for companies like Cellectar

• Negative EBITDA: Most oncology biotech firms at the clinical‑stage are still investing heavily in R&D, leading to operating losses. A negative denominator makes the ratio undefined or misleading.
  
• Alternative metrics are preferred: Analysts typically rely on EV/Revenue, Price/Book, Price/Fair‑Value of Pipeline, or Discounted Cash‑Flow (DCF) models that incorporate the net present value (NPV) of future product revenues rather than current earnings.

5. Example (illustrative only – do not treat as actual data)

Interpretation of the illustration:

- Cellectar’s EV/Revenue looks high because its revenue base is still tiny.

- All peers show negative EBITDA, reinforcing that EV/EBITDA isn’t a discriminating metric at this stage.

- The more informative comparison is the pipeline valuation (e.g., NPV of the lead candidate, TCR‑targeted therapy) rather than pure revenue multiples.

6. Practical next steps for you

1. Pull the latest numbers (market cap, cash, debt, revenue) from a reliable data source (Bloomberg, Refinitiv, Yahoo Finance, or the company’s 10‑Q filed with the SEC).
   
2. Calculate EV/Revenue as shown above.
   
3. Identify a peer set (≥5 comparable late‑stage oncology biotech firms).
   
4. Create a simple spreadsheet that lists each company’s EV, revenue, and the resulting EV/Revenue. Highlight the median and quartiles.
   
5. Interpret:
   
   • If Cellectar’s multiple is above the 75th percentile, the market may be pricing in a higher probability of success for its pipeline (or expecting a near‑term product launch).
     
   • If it’s below the 25th percentile, the stock could be undervalued or the market may view its pipeline as riskier.
     
6. Supplement the analysis with qualitative factors: stage of lead candidate (e.g., Phase III), competitive landscape, partnership agreements, cash runway, and upcoming catalysts (e.g., the Aug 14 earnings call you referenced).

7. Bottom line

• The press release alone does not provide EV/Revenue or EV/EBITDA data.
  
• You can compute these multiples using publicly available financial statements and market data.
  
• For oncology biotech firms at Cellectar’s stage, EV/Revenue is the more relevant multiple; EV/EBITDA is usually not meaningful because EBITDA tends to be negative.
  
• Benchmarking against a peer set will reveal whether Cellectar is trading at a premium or discount relative to its peers, but the ultimate valuation hinges on the perceived value of its clinical pipeline rather than historical earnings.

If you retrieve the raw numbers and would like help interpreting the resulting multiples, feel free to share them and I can walk you through a more detailed comparative analysis.